Early Neuromodulation in Traumatic Brain Injury

Background: Traumatic Brain Injury (TBI) is a medical and surgical epidemic affecting at least 1.7 million individuals yearly in the United States. Functional outcomes after TBI can show improvement or deterioration up to two decades after injury, and rates of all-cause mortality remain elevated for many years. Cognitive impairments are among the most disabling of post-TBI symptoms and typically contribute more to persisting disability than physical impairment. Following TBI, deficits are consistently demonstrated in the domains of attention, working memory and executive functioning. To date, there are some potential interventions for motor/functional recovery but there is no treatment for cognitive dysfunction which is more disabling. Although brain stimulation techniques appear promising as treatments to improve neuropsychiatric conditions and functional deficits, most noninvasive brain stimu¬lation interventions have been nontargeted and focused on the chronic phase of recovery after TBI. In the acute stages, there is limited available evidence of the efficacy and safety of brain stimulation to improve outcomes. The stimulation during chronic phase is applied either in isolation or before cognitive training. TBI thus underscores a major unaddressed challenge: the lack of time sensitive cognitive rehabilitation therapy post injury. Thus, there is an urgent need to develop rehabilitation paradigms in the early phases of injury for cognitive recovery and prevention of long-term cognitive impairments.

Hypothesis/Objective(s): This study is based on the hypothesis that early intervention with anodal transcranial electrical stimulation (A-tES) during the acute and sub-acute phases of TBI will enhance cognitive recovery over a similar intervention used only in the sub-acute phase. The objective of this study is to determine neural biomarkers of cognitive functional recovery in TBI and to investigate the neuromodulatory effects of early A-tES on cognitive functions in the sub-acute/chronic phases of TBI.

Specific Aims: (1) To determine neural correlates of cognitive recovery from injury over the acute to sub-acute/chronic phase in TBI, (2) To determine effects of time from injury when A-tES was administered on cognitive performance and associated EEG rhythms in TBI.

Study Design: The investigators will conduct a pilot clinical trial over a 3-year period in which we aim to recruit 60 patients with moderate to severe isolated TBI at the University of Cincinnati Medical Center (UCMC). All recruited participants will be administered a Brief test of adult cognition (BTACT) at bedside during the acute phase. They will perform 2 cognitive tasks on a laptop computer while their EEGs are being recorded. 50% of recruited patients selected randomly during the acute phase will receive active A-tES to their left dorsolateral prefrontal cortex (dlPFC) for 15 minutes each during the performance of cognitive tasks while the rest will receive sham stimulation. All participants will be followed for 6 months. When they return for their typical 3-month follow-up, we will perform another session with BTACT, EEG and cognitive tasks. During this visit all participants will receive active A-tES to their left dlPFC while performing cognitive tasks. In their last visit at 6 months post injury, all participants will be administered BTACT and cognitive tasks with EEG recordings but no intervention. They will also complete a quality of life (QOL) questionnaire designed through involvement of CBPR during their follow-up visits. For Aim 1, the investigators will determine if there are significant temporal correlations between neural oscillations recorded via EEG during the performance of cognitive tasks and injury phase. For Aim 2, the investigators will use a double-blind, randomized, sham-controlled, parallel study design to assess effects of early A-tES on improving performance on computer tasks, clinical test ratings and QOL measures during the 6-month post injury follow-up compared to A-tES delivered during the 3-month follow up visit.